These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 11511020)

  • 1. Matrix metalloproteinases in the progression of heart failure: potential therapeutic implications.
    Li YY; Feldman AM
    Drugs; 2001; 61(9):1239-52. PubMed ID: 11511020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure?
    Creemers EE; Cleutjens JP; Smits JF; Daemen MJ
    Circ Res; 2001 Aug; 89(3):201-10. PubMed ID: 11485970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MMP inhibition modulates TNF-alpha transgenic mouse phenotype early in the development of heart failure.
    Li YY; Kadokami T; Wang P; McTiernan CF; Feldman AM
    Am J Physiol Heart Circ Physiol; 2002 Mar; 282(3):H983-9. PubMed ID: 11834496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Matrix metalloproteinase inhibition and the prevention of heart failure.
    Lee RT
    Trends Cardiovasc Med; 2001 Jul; 11(5):202-5. PubMed ID: 11597832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling.
    Li YY; McTiernan CF; Feldman AM
    Cardiovasc Res; 2000 May; 46(2):214-24. PubMed ID: 10773225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myocardial remodelling and matrix metalloproteinases in heart failure: turmoil within the interstitium.
    Wilson EM; Spinale FG
    Ann Med; 2001 Dec; 33(9):623-34. PubMed ID: 11817657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myocardial matrix degradation and metalloproteinase activation in the failing heart: a potential therapeutic target.
    Spinale FG; Coker ML; Bond BR; Zellner JL
    Cardiovasc Res; 2000 May; 46(2):225-38. PubMed ID: 10773226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Matrix metalloproteinases: pathways of induction by bioactive molecules.
    Tsuruda T; Costello-Boerrigter LC; Burnett JC
    Heart Fail Rev; 2004 Jan; 9(1):53-61. PubMed ID: 14739768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Matrix metalloproteinases: regulation and dysregulation in the failing heart.
    Spinale FG
    Circ Res; 2002 Mar; 90(5):520-30. PubMed ID: 11909815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Matrix Metalloproteinases in Myocardial Infarction and Heart Failure.
    DeLeon-Pennell KY; Meschiari CA; Jung M; Lindsey ML
    Prog Mol Biol Transl Sci; 2017; 147():75-100. PubMed ID: 28413032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Matrix metalloproteinases, inflammation and atherosclerosis: therapeutic perspectives.
    Beaudeux JL; Giral P; Bruckert E; Foglietti MJ; Chapman MJ
    Clin Chem Lab Med; 2004 Feb; 42(2):121-31. PubMed ID: 15061349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Involvement of matrix metalloproteinases in the regulation of myocardial extracellular matrix in patients with congestive heart failure].
    Yang YJ; Zhang X; Zhu WL; Huang Y
    Zhonghua Yi Xue Za Zhi; 2006 Jun; 86(24):1693-6. PubMed ID: 16854324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel therapeutic approaches targeting matrix metalloproteinases in cardiovascular disease.
    Briasoulis A; Tousoulis D; Papageorgiou N; Kampoli AM; Androulakis E; Antoniades C; Tsiamis E; Latsios G; Stefanadis C
    Curr Top Med Chem; 2012; 12(10):1214-21. PubMed ID: 22519451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective matrix metalloproteinase inhibition with developing heart failure: effects on left ventricular function and structure.
    King MK; Coker ML; Goldberg A; McElmurray JH; Gunasinghe HR; Mukherjee R; Zile MR; O'Neill TP; Spinale FG
    Circ Res; 2003 Feb; 92(2):177-85. PubMed ID: 12574145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myocardial extracellular matrix remodeling in ischemic heart failure.
    Gallagher GL; Jackson CJ; Hunyor SN
    Front Biosci; 2007 Jan; 12():1410-9. PubMed ID: 17127391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MMP inhibition and the development of cerebrovascular atherosclerosis: The road ahead.
    Napoli C
    Stroke; 2002 Dec; 33(12):2864-5. PubMed ID: 12494909
    [No Abstract]   [Full Text] [Related]  

  • 17. Inhibitor of lysyl oxidase improves cardiac function and the collagen/MMP profile in response to volume overload.
    El Hajj EC; El Hajj MC; Ninh VK; Gardner JD
    Am J Physiol Heart Circ Physiol; 2018 Sep; 315(3):H463-H473. PubMed ID: 29775412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic implications of the specific inhibition of causative matrix metalloproteinases in experimental colitis induced by dextran sulphate sodium.
    Kobayashi K; Arimura Y; Goto A; Okahara S; Endo T; Shinomura Y; Imai K
    J Pathol; 2006 Jul; 209(3):376-83. PubMed ID: 16552705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Matrix metalloproteinase inhibitors: a review on pharmacophore mapping and (Q)SARs results.
    Kontogiorgis CA; Papaioannou P; Hadjipavlou-Litina DJ
    Curr Med Chem; 2005; 12(3):339-55. PubMed ID: 15723623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alteration of matrix metalloproteinases in selective left ventricular adriamycin-induced cardiomyopathy in the pig.
    Goetzenich A; Hatam N; Zernecke A; Weber C; Czarnotta T; Autschbach R; Christiansen S
    J Heart Lung Transplant; 2009 Oct; 28(10):1087-93. PubMed ID: 19782292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.